Precision BioSciences, Inc. Common Stock
$6.67
$0.00 (+0.00%)
$6.57Day Range$6.87
Key Statistics
Market Cap
$184.10M
Shares Outstanding
27.6M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Mar 28, 2019
Round Lot
100
Locale
US
Trading Data
Day Open
$6.65
Day High
$6.87
Day Low
$6.57
Volume
241.4K
VWAP
$6.66
Prev Close
$6.67
Transactions
--
Acc. Volume
--
About Precision BioSciences, Inc. Common Stock
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 283667 employees302 EAST PETTIGREW STREET, DURHAM, NC, 27701919-314-5512IPO Mar 28, 2019US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001357874
- Composite FIGI
- BBG008NSBPV3
- Share Class FIGI
- BBG008NSBPW2
- Ticker Root
- DTIL
- SIC Code
- 2836
About Precision BioSciences, Inc. Common Stock (DTIL) Stock
Precision BioSciences, Inc. Common Stock (DTIL) closed the 2026-09-18 session at $6.67, up 0.00% versus the previous close (+0.00). The stock opened at $6.65 and traded between $6.57 and $6.87 during that session. Session trading volume was 241K shares. The volume-weighted average price (VWAP) is $6.66.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
Precision BioSciences, Inc. Common Stock has a market capitalization of $184.1 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. DTIL is listed on the XNAS exchange. The company employs approximately 67 people. Precision BioSciences, Inc. Common Stock is headquartered in DURHAM, NC. The recorded listing date is 2019-03-28.
On this page you can find market DTIL stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.